[HTML][HTML] Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T

DH Yoon, MJ Osborn, J Tolar, CJ Kim - International journal of molecular …, 2018 - mdpi.com
Chimeric antigen receptor (CAR) T cell therapy represents the first US Food and Drug
Administration approved gene therapy and these engineered cells function with …

[HTML][HTML] Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study

LE Budde, S Assouline, LH Sehn… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With
Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study - PMC Back to Top …

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim… - The lancet …, 2016 - thelancet.com
Background The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has
improved substantially as a result of new treatment strategies with non-anthracycline-based …

[HTML][HTML] Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor

C Yoo, DH Yoon, C Suh - Blood research, 2014 - ncbi.nlm.nih.gov
Beta-2 microglobulin is synthesized in all nucleated cells and forms the light chain subunit of
the major histocompatibility complex class I antigen. Despite its potential role as a …

[HTML][HTML] ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell …

GS Nowakowski, A Chiappella… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic …

JE Kim, DH Lee, Y Choi, DH Yoon, SW Kim, C Suh… - Lung Cancer, 2009 - Elsevier
Considering whole-brain radiotherapy (WBRT) for asymptomatic brain metastases can
reduce performance status and delay systemic treatment, primary chemotherapy can be a …

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

MA Dimopoulos, F Gay, F Schjesvold, M Beksac… - The Lancet, 2019 - thelancet.com
Background Maintenance therapy following autologous stem cell transplantation (ASCT)
can delay disease progression and prolong survival in patients with multiple myeloma …

[HTML][HTML] Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving …

YR Kim, JS Kim, YH Min, DH Yoon, HJ Shin… - Journal of Hematology & …, 2012 - Springer
Background The objective of this study was to identify prognostic factors for survival in
patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. Methods …

Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II …

SJ Kim, DH Yang, JS Kim, JY Kwak, HS Eom… - Annals of …, 2014 - Springer
We conducted a phase II trial of concurrent chemoradiotherapy (CCRT) followed by 2 cycles
of l-asparaginase-containing chemotherapy for patients who were newly diagnosed with …

[HTML][HTML] Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial

SJ Kim, DH Yoon, HJ Kang, JS Kim, SK Park… - European journal of …, 2012 - Elsevier
BACKGROUND: We performed a phase II study to evaluate the efficacy of bortezomib in
combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) as …